BMS’s Subcutaneous Opdivo Meets Phase III Study Endpoints in ccRCC
Bristol-Myers Squibb (BMS; NYSE: BMY) has announced positive results from a Phase III comparative study...
Novo Nordisk Partners with GE HealthCare to Develop Non-Invasive Treatment for Chronic Diseases
Metabolism expert Novo Nordisk (NYSE: NVO) has announced a partnership with medical technology firm GE...
MSD Collaborates with Daiichi Sankyo on Development of Innovative ADC Candidates
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced a strategic collaboration agreement with Japan-based...
HuidaGene Receives FDA Rare Pediatric Disease Designation for MECP2 Syndrome Therapy
China-based HuidaGene (Shanghai) Biotechnology Co., Ltd has announced that it has received Rare Pediatric Disease...
Kyowa Hakko Kirin Doubles Manufacturing Capacity with Shanghai Plant Expansion
Japan-based biopharmaceutical company Kyowa Hakko Kirin has announced the successful completion and operational status of...
Sansure Biotech Partners with Shaanxi Lifegen to Boost Molecular Diagnostics
China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) has formed a strategic partnership with...
Alebund Pharmaceuticals Secures Exclusive Rights to Roche’s Mircera in China
Shanghai-based Alebund Pharmaceuticals has entered into a commercialization agreement with Swiss pharmaceutical giant Roche (SWX:...
AstraZeneca’s Soliris Gains Approval in China for NMOSD Treatment
UK-based pharmaceutical giant AstraZeneca Plc (AZ, NASDAQ: AZN) has announced that its rare disease drug...
CNIPA Upholds Alnylam’s PCSK9-Targeted siRNA Patent Against Junshi Biosciences Challenge
The China National Intellectual Property Administration (CNIPA) has rejected another challenge from Junshi Biosciences (SHA:...
Qilu Pharmaceutical Presents Promising Data for QL1706 and QL1209 at ESMO 2023
China-based Qilu Pharmaceutical has announced the presentation of clinical data for two of its pipeline...
Guangdong Zhongsheng Launches AI Q&A Bot for Leritrelvir Drug Support
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced the innovative launch of a...
WuXi XDC Partners with Hong Kong Science Park to Boost CRDMO Value Chain
WuXi XDC, a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA, a subsidiary...
AlphaGen Therapeutics Secures Seed Funding for Pb-212 Radioligand Therapy Development
AlphaGen Therapeutics Ltd, a Shanghai-based developer specializing in radioligand therapy (RLT), has reportedly secured “tens...
Boehringer Ingelheim’s Vitiligo Drug EI-001 Approved for Clinical Trials by NMPA
Germany’s Boehringer Ingelheim (BI) has announced that the National Medical Products Administration (NMPA) has approved...
Pharmaron Beijing to Establish Singapore JV Rxilient Biohub for CDMO Services
China-based Contract Development and Manufacturing Organization (CDMO) Pharmaron Beijing Co., Ltd (HKG: 3759, SHE: 300759)...
Haisco Pharmaceutical’s HSK21542 Accepted for NMPA Review in Postoperative Pain Management
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that its clinical trial filing...
NMPA Issues Guidelines for Temporary Import of Urgently Needed Medical Devices
The National Medical Products Administration (NMPA) has released new “Management Requirements for Temporary Import and...
Abbott Reports 8.7% Drop in Q3 2023 Global Sales, Hit by Lower SARS-CoV-2 Test Demand
Abbott (NYSE: ABT) published its Q3 2023 financial results this week, reporting a 8.7% year-on-year...
Roche’s Alecensa Shows Unprecedented 76% Improvement in Disease-Free Survival in NSCLC Trial
Roche (SWX: ROG) subsidiary Genentech has revealed preliminary but promising results from a Phase III...
Eli Lilly Acquires Mablink Bioscience to Expand Next-Gen ADC Portfolio
US pharmaceutical company Eli Lilly (NYSE: LLY) has signed an agreement to acquire France-based Mablink...